anonymous
Guest
anonymous
Guest
Why the late wait? FDA didn’t approve when the interviewers said. Red flag.Retired drug rep here and neuropathy sufferer. Suzetrigine has the potential to be a blockbuster just in neuropathy! Neurologists have long been excited about the introduction of a calcium channel blocker to treat neuropath. IF this drug works well for neuropathic pain, you will definitely have a blockbuster. With a PDUFA date of January 25, 2025, it won’t be long now.